Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.

Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing